Abstract
Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have